Identification and triage of patients with incidental germline pathogenic variants on somatic tumor profiling with a genomics module

IF 1.9 4区 医学 Q3 GENETICS & HEREDITY
Jenna Harris, Nicole Horton, Karen Huelsman
{"title":"Identification and triage of patients with incidental germline pathogenic variants on somatic tumor profiling with a genomics module","authors":"Jenna Harris,&nbsp;Nicole Horton,&nbsp;Karen Huelsman","doi":"10.1002/jgc4.70071","DOIUrl":null,"url":null,"abstract":"<p>When cancer patients undergo tumor profile testing with paired tumor tissue and germline samples, incidental germline pathogenic variants are identified in up to 1 of 8 cases. Genetic counselors (GCs) play an important role in identifying these patients for genetic counseling referral and confirmatory germline testing. Tumor profile tests are typically ordered by medical oncologists, so a collaborative partnership with GCs supports appropriate follow-up. Manual methods to identify these patients can be time-consuming and tedious. In 2020, our team implemented a genomics module in the electronic health record system (EHR) and completed integration with the tumor testing laboratory. We used discrete variants in our EHR to create a reporting workbench tool to identify patients with incidental germline pathogenic variants. A protocol for triaging flagged patients to traditional vs. embedded care confirmatory germline testing was developed for appropriate referral. Patients were considered eligible for GC referral and confirmatory germline testing after excluding those who were deceased, previously tested, or declined confirmatory germline testing with documentation in the EHR. From 2020 to 2024, the GC referral rate increased from 27% to 100% and the confirmatory germline testing rate increased from 27% to 66%. Of all incidental germline pathogenic variants that underwent confirmatory germline testing, 100% were confirmed. Confirmatory germline testing did reveal secondary pathogenic variants not reported initially on tumor profile tests. We found additional pathogenic variants in 8.6% (2/23) and 9.7% (3/31) of patients tested in 2023 and 2024, respectively. Between 2019 and 2024, 192 total incidental germline patients were identified. The proportion of patients who underwent tumor profile testing with incidental germline findings was 7.3% overall, which is concordant with previously reported study rates. Discrete identification of potential germline variants via EHR integration supported the efficient triaging of patients eligible for GC referral and confirmatory germline testing, contributing to a 100% referral rate in 2024. Integration of the testing laboratory creates opportunity for further EHR application, such as Best Practice Alerts and Health Maintenance Care Gaps. Building laboratory integration for discrete genomic variants increases reporting capabilities, patient tracking, cascade testing, and could be applied to many broader medical contexts.</p>","PeriodicalId":54829,"journal":{"name":"Journal of Genetic Counseling","volume":"34 3","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Genetic Counseling","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgc4.70071","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

When cancer patients undergo tumor profile testing with paired tumor tissue and germline samples, incidental germline pathogenic variants are identified in up to 1 of 8 cases. Genetic counselors (GCs) play an important role in identifying these patients for genetic counseling referral and confirmatory germline testing. Tumor profile tests are typically ordered by medical oncologists, so a collaborative partnership with GCs supports appropriate follow-up. Manual methods to identify these patients can be time-consuming and tedious. In 2020, our team implemented a genomics module in the electronic health record system (EHR) and completed integration with the tumor testing laboratory. We used discrete variants in our EHR to create a reporting workbench tool to identify patients with incidental germline pathogenic variants. A protocol for triaging flagged patients to traditional vs. embedded care confirmatory germline testing was developed for appropriate referral. Patients were considered eligible for GC referral and confirmatory germline testing after excluding those who were deceased, previously tested, or declined confirmatory germline testing with documentation in the EHR. From 2020 to 2024, the GC referral rate increased from 27% to 100% and the confirmatory germline testing rate increased from 27% to 66%. Of all incidental germline pathogenic variants that underwent confirmatory germline testing, 100% were confirmed. Confirmatory germline testing did reveal secondary pathogenic variants not reported initially on tumor profile tests. We found additional pathogenic variants in 8.6% (2/23) and 9.7% (3/31) of patients tested in 2023 and 2024, respectively. Between 2019 and 2024, 192 total incidental germline patients were identified. The proportion of patients who underwent tumor profile testing with incidental germline findings was 7.3% overall, which is concordant with previously reported study rates. Discrete identification of potential germline variants via EHR integration supported the efficient triaging of patients eligible for GC referral and confirmatory germline testing, contributing to a 100% referral rate in 2024. Integration of the testing laboratory creates opportunity for further EHR application, such as Best Practice Alerts and Health Maintenance Care Gaps. Building laboratory integration for discrete genomic variants increases reporting capabilities, patient tracking, cascade testing, and could be applied to many broader medical contexts.

用基因组学模块鉴定和分诊偶发种系致病变异的躯体肿瘤患者
当癌症患者接受配对肿瘤组织和种系样本的肿瘤谱检测时,在多达1 / 8的病例中发现偶然的种系致病变异。遗传咨询师(GCs)在确定这些患者进行遗传咨询转诊和确认生殖系检测方面发挥着重要作用。肿瘤特征测试通常由内科肿瘤学家进行,因此与GCs的合作伙伴关系支持适当的随访。手动识别这些患者的方法既费时又乏味。2020年,我们的团队在电子健康记录系统(EHR)中实现了基因组学模块,并完成了与肿瘤检测实验室的集成。我们在我们的电子病历中使用离散变异来创建一个报告工作台工具,以识别附带种系致病变异的患者。为适当的转诊制定了对标记患者进行传统与嵌入式护理确认性生殖细胞检测的分类方案。在排除了死亡、先前检测或拒绝EHR记录的确认性生殖系检测的患者后,患者被认为有资格进行GC转诊和确认性生殖系检测。从2020年到2024年,GC转诊率从27%提高到100%,确认性种系检测率从27%提高到66%。所有附带的种系致病变异进行了确认性种系检测,100%得到确认。确证性种系检测确实揭示了最初在肿瘤谱检测中未报告的继发性致病变异。我们在2023年和2024年分别在8.6%(2/23)和9.7%(3/31)的检测患者中发现了额外的致病变异。在2019年至2024年期间,共发现了192例附带生殖系患者。总体而言,接受肿瘤谱检测并附带生殖系发现的患者比例为7.3%,这与先前报道的研究率一致。通过EHR整合对潜在生殖系变异进行离散识别,支持对有资格进行GC转诊和确认性生殖系检测的患者进行有效分类,从而在2024年实现100%的转诊率。测试实验室的集成为进一步的EHR应用创造了机会,例如最佳实践警报和健康维护护理差距。为离散基因组变异构建实验室集成可以提高报告能力、患者跟踪、级联测试,并可应用于许多更广泛的医学环境。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Genetic Counseling
Journal of Genetic Counseling GENETICS & HEREDITY-
CiteScore
3.80
自引率
26.30%
发文量
113
审稿时长
6 months
期刊介绍: The Journal of Genetic Counseling (JOGC), published for the National Society of Genetic Counselors, is a timely, international forum addressing all aspects of the discipline and practice of genetic counseling. The journal focuses on the critical questions and problems that arise at the interface between rapidly advancing technological developments and the concerns of individuals and communities at genetic risk. The publication provides genetic counselors, other clinicians and health educators, laboratory geneticists, bioethicists, legal scholars, social scientists, and other researchers with a premier resource on genetic counseling topics in national, international, and cross-national contexts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信